News
ENTA
9.34
+0.32%
0.03
Enanta Pharmaceuticals Inc <ENTA.OQ> expected to post a loss of $1.16 a share - Earnings Preview
Reuters · 10h ago
Enanta Pharma's Earnings Outlook
Benzinga · 16h ago
Weekly Report: what happened at ENTA last week (1111-1115)?
Weekly Report · 4d ago
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/14 20:25
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/12 22:25
Weekly Report: what happened at ENTA last week (1104-1108)?
Weekly Report · 11/11 09:27
Weekly Report: what happened at ENTA last week (1028-1101)?
Weekly Report · 11/04 09:28
Weekly Report: what happened at ENTA last week (1021-1025)?
Weekly Report · 10/28 09:25
Weekly Report: what happened at ENTA last week (1014-1018)?
Weekly Report · 10/21 09:25
Weekly Report: what happened at ENTA last week (1007-1011)?
Weekly Report · 10/14 09:30
Enanta Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Dow Jones · 10/10 11:23
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target
Benzinga · 10/10 11:16
Buy Rating Affirmed for Enanta Pharmaceuticals on Strong Clinical Trial Outcomes and Promising Pipeline Valuation
TipRanks · 10/10 10:25
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts
Benzinga · 10/09 19:02
Enanta Pharmaceuticals Price Target Maintained With a $22.00/Share by JMP Securities
Dow Jones · 10/09 18:18
JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $22 Price Target
Benzinga · 10/09 18:08
Buy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug Trials
TipRanks · 10/09 04:55
Weekly Report: what happened at ENTA last week (0930-1004)?
Weekly Report · 10/07 09:28
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Simply Wall St · 10/05 13:42
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
NASDAQ · 10/02 11:53
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).